Gallbladder Cancer: Causes, Symptoms, and Treatments

Gallbladder cancer is uncommon but aggressive, with most cases diagnosed only after the tumor has already spread beyond the gallbladder wall. Worldwide, roughly 122,000 new cases and 89,000 deaths were estimated in 2022, and about two-thirds of those affected were women.¹ Its main risk factor is longstanding gallstones, and its prognosis varies enormously depending on when it is caught. A large global review covering more than 320,000 patients found that five-year survival has barely budged over the past three decades, which makes understanding what causes it, how to spot it, and what treatments exist all the more important.²

Who Gets Gallbladder Cancer and Where

One of the striking features of this cancer is how unevenly it is distributed across the globe. The highest recorded rates show up in northeastern India and southern Chile, where women face incidence rates around 15 per 100,000, roughly double the rate in men from the same areas. The lowest rates are found in parts of sub-Saharan Africa, and the gap between the highest- and lowest-risk populations spans about a hundredfold.¹ Chile had the highest age-standardized incidence and death rates at the national level as of 2017.³

Genetics and ethnicity play a measurable role. About a quarter of cases are considered familial, and certain populations, particularly Native Americans, face disproportionately high risk.⁴ The disease is also more common in older adults and, as noted, considerably more common in women. These patterns are not fully explained by gallstone prevalence alone, which suggests that genetic susceptibility, diet, environmental exposures, and chronic infections all contribute to the geographic mosaic of risk.

Gallstones and the Path to Cancer

The single most well-established risk factor for gallbladder cancer is prolonged exposure to gallstones. The risk appears to climb with stone size.⁵ What matters is not so much the stones themselves but the chronic inflammation they provoke. The gallbladder lining endures repeated cycles of damage and repair, and over years this creates conditions that push normal cells through a sequence of increasingly abnormal changes, from metaplasia (cells changing type) to dysplasia (cells looking abnormal under a microscope) and eventually to cancer.⁶

That said, most people with gallstones never develop cancer. The disease remains rare even among gallstone patients. Chronic inflammation simply creates the environment where genetic damage accumulates faster than normal. Bacterial infections, including typhoid carrier status and Helicobacter pylori, contribute to this inflammatory burden, and so do certain anatomical abnormalities of the bile duct system.⁴ One such abnormality, called an anomalous pancreaticobiliary duct junction, allows pancreatic juices to flow backward into the gallbladder. In a study of 218 gallbladder cancer patients, about 5% had this duct anomaly, and gallstones were absent in nine of those ten cases, suggesting the abnormal reflux itself can drive cancer independently of stones.⁷

What Goes Wrong at the Genetic Level

The gene most commonly disrupted in gallbladder cancer is TP53, the same tumor-suppressor gene implicated in a wide range of cancers. In one analysis, TP53 was altered in half of gallbladder cancer tissues.⁸ A global exome study confirmed TP53 as the most frequently mutated gene, alongside MUC16, ELF3, and ARID2.⁹ Other alterations include EGFR, RB1, and ERBB2 (also known as HER2). In one study, nearly 60% of gallbladder cancer cases carried gene changes that could potentially be targeted by existing drugs, which is a meaningful finding for treatment planning.⁸

In patients with the duct abnormality mentioned earlier, TP53 mutations followed a stepwise pattern: 10% in normal tissue, 38% in tissue adjacent to the tumor, and 75% in the tumor itself. That gradient supports the idea that chronic irritation drives a slow accumulation of mutations rather than a sudden transformation.

Why Symptoms Come Late

Gallbladder cancer is notoriously silent in its early stages. The gallbladder is a small pouch tucked behind the liver, and early tumors cause no pain and no obvious disruption to digestion. When symptoms do appear, they tend to be vague: dull pain in the upper-right abdomen, nausea, bloating, or loss of appetite. These symptoms overlap heavily with gallstones and other benign gallbladder conditions, so they rarely trigger immediate alarm.¹⁰

By the time more distinctive signs develop, such as jaundice (yellowing of the skin and eyes from bile duct obstruction), unexplained weight loss, or a palpable lump in the abdomen, the cancer has usually advanced to regional or distant spread. This delayed presentation is the central reason outcomes are so poor: the disease progresses silently, and by the time it declares itself, the window for curative treatment has often closed.

How It Is Diagnosed

Ultrasound is usually the first imaging test, and it can flag suspicious thickening of the gallbladder wall or polyps that need closer evaluation.¹¹ CT scanning is the standard for staging because it shows the gallbladder, liver, lymph nodes, and distant organs in a single exam. MRI adds better soft-tissue detail and is particularly useful for evaluating whether the cancer has invaded the bile ducts.¹² In practice, many patients undergo both CT and MRI as clinicians piece together the full picture.

Staging follows the system established by the American Joint Committee on Cancer (AJCC). The most recent edition subdivides certain tumor categories to better predict outcomes. For example, tumors that invade through the muscle layer of the gallbladder wall are now classified differently depending on whether they face the liver side or the abdominal cavity side, because location affects spread patterns and survival. The updated lymph node staging counts the number of involved nodes rather than relying on their anatomical location, and recommends examining at least six nodes for accurate classification.¹³

Surgery as the Primary Cure

Surgery offers the only real chance of cure, and what type of operation you need depends entirely on how deep the tumor has grown. For the earliest-stage cancers (those confined to the mucosa, called Tis or T1a), a standard laparoscopic cholecystectomy, meaning simple removal of the gallbladder, is generally sufficient and carries a good prognosis.¹⁴

For tumors that have grown deeper into the gallbladder wall (T1b and beyond), the standard of care is a radical cholecystectomy. This involves removing the gallbladder along with a wedge of the adjacent liver tissue and the regional lymph nodes. It is a bigger operation, and it requires an experienced surgical team. One recent analysis found that for T1b cancers specifically, outcomes after simple cholecystectomy were comparable to those after radical resection in highly selected patients who had clear margins and no signs of residual disease on imaging. But the authors cautioned that radical surgery remains the standard until prospective trials can validate a simpler approach for this subgroup.¹⁵

When Cancer Is Found by Accident

A surprisingly common scenario is the discovery of gallbladder cancer after a routine cholecystectomy performed for gallstones or gallbladder inflammation. The pathologist examines the removed gallbladder and finds cancer that nobody suspected. This is called incidental gallbladder cancer, and how it is managed matters a great deal.

For the shallowest tumors (T1a), simple cholecystectomy alone may be adequate, provided the margins are clear and the specimen was removed intact without any rupture or spillage.¹⁶ For T1b and more advanced tumors found incidentally, a second operation to perform a radical resection is recommended. The reoperation includes removing the gallbladder bed tissue from the liver and clearing the regional lymph nodes.¹⁷

If cancer is recognized during surgery rather than after, immediately converting to a radical resection appears to produce fewer complications and better survival compared with closing up and coming back for a second operation later.¹⁸ Use of a specimen retrieval bag during laparoscopic cholecystectomy is an important precaution: it reduces the risk of cancer cells seeding into the port sites, which can cause recurrence at the wound.¹⁶

Chemotherapy and Newer Drug Treatments

For advanced gallbladder cancer that cannot be removed surgically, the backbone of systemic treatment has been the combination of gemcitabine and cisplatin. Adding immunotherapy to that backbone has shifted the landscape. The TOPAZ-1 trial tested durvalumab, a PD-L1 inhibitor, on top of gemcitabine plus cisplatin in patients with advanced biliary tract cancers, including gallbladder cancer. Patients who received durvalumab lived longer overall, with a roughly 20% reduction in the risk of death compared with chemotherapy alone. At two years, about a quarter of the durvalumab group was still alive, compared with roughly one in ten in the placebo group.¹⁹

On the basis of that trial and similar data, adding a checkpoint inhibitor to first-line chemotherapy has become a new standard for advanced disease. Case reports also describe individual patients achieving complete responses with this combination, though those remain the exception rather than the rule.²⁰

Earlier trials with checkpoint inhibitors alone showed more modest results. In the KEYNOTE-028 and KEYNOTE-158 studies, pembrolizumab produced objective response rates of about 13% and 6% respectively, but responses that did occur tended to last.²¹ These results suggest that immunotherapy works best in combination with chemotherapy rather than as a standalone approach in unselected patients.

In the adjuvant setting, meaning after surgery with the intent of preventing recurrence, a randomized trial of gemcitabine plus cisplatin showed encouraging results: estimated two-year disease-free survival reached about 75%.²² Adjuvant therapy remains an active area of research, and decisions about whether to pursue it after surgery depend on the tumor’s stage and individual risk factors.

Radiation Therapy

Radiation plays a more limited role in gallbladder cancer than in many other solid tumors, but it is not irrelevant. For tumors that cannot be removed surgically, combining radiation with chemotherapy has been associated with better survival than chemotherapy alone in analyses of large national databases. Modern techniques allow higher doses to be delivered with less damage to surrounding tissue, making this approach more feasible than it was a generation ago.²³ Radiation is also used after surgery in certain high-risk situations, though its benefit in the adjuvant setting is still debated.

Palliative Care for Advanced Disease

Because the majority of gallbladder cancer cases are advanced at diagnosis, palliative care is a critical part of management. Jaundice caused by bile duct blockage is one of the most distressing symptoms and is typically relieved through biliary drainage. The most common approach is endoscopic: a stent is placed through the bile duct during an endoscopy procedure to hold the duct open and allow bile to flow again.²⁴

When endoscopic drainage fails or is not possible due to the tumor’s location or altered anatomy, a percutaneous drain placed through the skin into the bile duct is an alternative. A randomized trial comparing the two approaches found that percutaneous drainage was more often successful (89% versus 41%) and caused less early infection, though survival was similar at about 60 days in both groups. Quality-of-life scores at three months also favored percutaneous drainage.²⁵ Pain management and fluid drainage for ascites (fluid buildup in the abdomen) are other common palliative interventions.²⁶

Survival by Stage

Prognosis hinges almost entirely on how far the cancer has spread at the time of diagnosis. An analysis of U.S. data from 1975 to 2021 found that localized gallbladder cancer, meaning tumor confined to the gallbladder, had a five-year survival rate of 68%. Younger patients did even better, with survival above 90% for those under 50. Once the cancer had spread to nearby tissues or lymph nodes (regional disease), survival dropped to about 28%. For distant metastatic disease, the figure fell to roughly 4%.²⁷

Globally, the picture is sobering. The highest five-year relative survival rates reported anywhere hover around 30%, seen in certain populations in China and Korea. The lowest figures dip to around 6%.² In the United States, incidence rates have been declining at about 2.4% per year since 1975, and mortality has followed a similar trajectory, likely driven by the increasing use of cholecystectomy for gallstone disease, which removes the organ before cancer can develop.²⁷

Histological Subtypes and What They Mean

The most common type of gallbladder cancer is adenocarcinoma, which accounts for the vast majority of cases. But rarer subtypes behave quite differently. Papillary gallbladder cancer tends to be caught at an earlier stage, has less lymph node involvement, and carries a median survival of about 44 months. At the other end of the spectrum, adenosquamous and squamous types present at more advanced stages, with more than half of patients having deeply invasive tumors at diagnosis. Median survival for those subtypes is about 7 months.²⁸

Neuroendocrine tumors of the gallbladder are another rare entity. They tend to present at a high grade and advanced stage, with nearly 40% already stage IV at diagnosis. While they have better survival than gallbladder adenocarcinoma overall, they fare worse than neuroendocrine tumors arising from other parts of the gastrointestinal tract.²⁹

The Porcelain Gallbladder Myth

For decades, a “porcelain gallbladder,” in which calcium deposits coat the gallbladder wall, was considered a strong indication for preventive removal due to a presumed high cancer risk. That thinking has changed. Systematic reviews now show the association between porcelain gallbladder and cancer is weak. Prophylactic cholecystectomy is no longer routinely recommended for porcelain gallbladder alone; surgery should be reserved for patients who have symptoms or other conventional reasons for removal.³⁰ Patients who do not have surgery should be educated about gallbladder disease symptoms, and decisions should factor in the calcification pattern, patient age, and overall health.³¹

Disparities in Who Gets Treated

Access to treatment for gallbladder cancer is not equal across racial and ethnic groups, at least in the United States. A large database study found that Black patients were significantly less likely to receive curative surgery compared with white patients, even after adjusting for other factors. Among patients who did undergo surgery, Hispanic patients were less likely to have adequate lymph node clearance, a measure of surgical quality.³² These gaps are concerning because, as described above, surgery is the only curative option. Being less likely to receive it translates directly into worse outcomes, compounding the biological disadvantage of an already-aggressive cancer.

1
PubMed Central. Global variations in gallbladder cancer incidence: What do recorded data and national estimates tell us?
2
PubMed Central. Global trends in gallbladder cancer survival: A 30-year analysis of cancer registry data
3
PubMed. The global, regional, and national burden of gallbladder and biliary tract cancer and its attributable risk factors in 195 countries and territories, 1990 to 2017
4
PubMed Central. Epidemiology of gallbladder cancer
5
PubMed. Carcinogenesis of malignant lesions of the gall bladder. The impact of chronic inflammation and gallstones
6
PubMed Central. The inflammatory inception of gallbladder cancer
7
PubMed Central. Gallbladder carcinoma associated with anomalous pancreaticobiliary duct junction
8
PubMed Central. Stepwise correlation of TP53 mutations from pancreaticobiliary maljunction to gallbladder carcinoma
9
PubMed Central. Geographic and genetic diversity in gallbladder cancer mutation profiles: insights from a worldwide exome analysis
10
PubMed Central. Gallbladder cancer: epidemiology and outcome
11
PubMed Central. Update on the Role of Imaging in the Diagnosis, Staging, and Prognostication of Gallbladder Cancer
12
PubMed. Gallbladder Carcinoma and Its Differential Diagnosis at MRI: What Radiologists Should Know
13
PubMed Central. Validation of the 8th Edition of the American Joint Committee on Cancer Staging System for Gallbladder Cancer and Implications for the Follow-up of Patients without Node Dissection
14
PubMed. Progress and controversy in minimally invasive approach to radical cholecystectomy for gallbladder cancer
15
PubMed. Simple versus radical cholecystectomy and survival for pathologic stage T1B gallbladder cancer
16
PubMed. Surgical treatment of incidental gallbladder cancer discovered during or following laparoscopic cholecystectomy
17
PubMed Central. Incidental gallbladder cancer after laparoscopic cholecystectomy: incidence management and prognosis
18
PubMed Central. Incidental gallbladder cancer detected during laparoscopic cholecystectomy: conversion to extensive resection is a feasible choice
19
PubMed. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
20
PubMed Central. Complete response of gallbladder cancer treated with gemcitabine and cisplatin chemotherapy combined with durvalumab
21
Signal Transduction and Targeted Therapy. Overview of current targeted therapy in gallbladder cancer
22
JAMA Oncology. Adjuvant Gemcitabine Plus Cisplatin and Chemoradiation in Patients With Gallbladder Cancer
23
Radiation Oncology Journal. Reviewing the potential role of radiation therapy in gallbladder cancer: an update
24
PubMed Central. Palliation in Gallbladder Cancer: The Role of Gastrointestinal Endoscopy
25
PubMed. Endoscopic or percutaneous biliary drainage for gallbladder cancer: a randomized trial and quality of life assessment
26
PubMed Central. Symptom Palliation in Advanced GallBladder Cancer: An Institutional Experience
27
Journal of Clinical Oncology. Long-term trends in gallbladder cancer incidence, mortality, and survival disparities
28
PubMed Central. Clinicopathological characteristics and outcomes of rare histologic subtypes of gallbladder cancer over two decades
29
PubMed Central. Primary Gallbladder Neuroendocrine Tumors: Insights into a Rare Histology Using a Large National Database
30
JAMA Surgery. Reassessing the Need for Prophylactic Surgery in Patients With Porcelain Gallbladder
31
PubMed Central. Management of Porcelain Gallbladder, Its Risk Factors, and Complications: A Review
32
PubMed Central. Racial/ethnic disparities in gallbladder cancer receipt of treatments